Krsnaa Diagnostics Ltd
NSE:KRSNAA
Krsnaa Diagnostics Ltd
Krsnaa Diagnostics Ltd. engages in the provision of diagnostics services. The company is headquartered in Pune, Maharashtra. The company went IPO on 2021-08-16. The firm is focused on providing radiology and pathology services for -radiation (X-rays), computed tomography (CT) scan, magnetic resonance imaging (MRI), mammography, tele- reporting services, and all types of blood and urine investigation. The firm operates within India and has diagnostic centers all over India. The Company' studies in CT Scan include Peripheral Angio, Urography, Coronary Angio, Cisternography, CT Brain, CT Abdomen Triple Phase, CT HRCT Temporal Bone, CT Dentascan, CT Brain Angio, CT Perfusion, CT Renal Angio, CT Aortography and CT Pulmonary Angio. The Company’s services in color doppler include upper limb arterial doppler, upper limb venous doppler, lower limb arterial doppler, lower limb venous doppler, carotid doppler, hepatosplenic doppler, obstetric doppler and scrotal doppler.
Krsnaa Diagnostics Ltd. engages in the provision of diagnostics services. The company is headquartered in Pune, Maharashtra. The company went IPO on 2021-08-16. The firm is focused on providing radiology and pathology services for -radiation (X-rays), computed tomography (CT) scan, magnetic resonance imaging (MRI), mammography, tele- reporting services, and all types of blood and urine investigation. The firm operates within India and has diagnostic centers all over India. The Company' studies in CT Scan include Peripheral Angio, Urography, Coronary Angio, Cisternography, CT Brain, CT Abdomen Triple Phase, CT HRCT Temporal Bone, CT Dentascan, CT Brain Angio, CT Perfusion, CT Renal Angio, CT Aortography and CT Pulmonary Angio. The Company’s services in color doppler include upper limb arterial doppler, upper limb venous doppler, lower limb arterial doppler, lower limb venous doppler, carotid doppler, hepatosplenic doppler, obstetric doppler and scrotal doppler.
Revenue Growth: Q3 revenue was INR 1,812 million, up 4% year-on-year, but growth was modest due to seasonality and temporary operational pauses for receivables recovery.
Receivables Recovery: Over INR 130 crores in government receivables were recovered in Q3, strengthening the cash position and reducing days outstanding.
Margin Impact: EBITDA margin was 26%, depressed by costs related to new project rollouts, especially Rajasthan; normalized margin was 27%.
Rajasthan Project: Major pathology project rollout is underway, with full revenue contribution of around INR 200 crores expected in FY '27.
Retail Growth: Retail diagnostic revenue grew nearly 8x year-on-year and now contributes about 8% to group revenue, with over 3,000+ retail touchpoints.
Capital Allocation Discipline: Management emphasized selective participation in new PPP tenders and heightened capital discipline after recent delays.
Outlook: Management expects operational headwinds to be temporary, with margin and revenue normalization as new projects ramp up in coming quarters.
